RUNX2 and renal cell carcinoma: In renal cell carcinoma, RUNX2 appeared to promote cancer cell invasion through the calpain2–fibronectin axis, and the RUNX2-overexpression-mediated effect was attenuated by the calpain inhibitor calpeptin or calpain2 small interfering RNA (siRNA) in A498 cells [32].